Transition to Basal Bolus

The prevailing practice of ‘sliding scale’ for subcutaneous insulin therapy has been largely denounced as ineffective and unsafe.


The American Diabetes Association, American Association of Clinical Endocrinologists, Endocrine Society, Society of Hospital Medicine and other authoritative sources discourage use of ‘sliding scale’ insulin.


However, in the absence of a technology-enabled systems approach with Glytec, best practice for subcutaneous insulin therapy, or ‘basal-bolus-correction,’ is inarguably challenging for clinicians. It requires a level of monitoring not easily accomplished through manual intervention and a level of knowledge not typically possessed outside the field of endocrinology.

“We knew that eliminating a well-established practice like sliding scale insulin would be challenging. However, Glytec provided us with great insights and strategies for overcoming the common barriers and achieving maximal utilization. They have proven to be an exceptional partner.”


Catherine Rolih, MD

Medical Director Diabetes Service Line, Novant Health 
Clinic Lead Inpatient and Subspecialty Diabetes, UPMC

We combine our patented and integrated eGlycemic Management System® with expert professional services to help facilitate and support clinical practice change as well as ongoing quality improvement.


Our efficient and evidence-based systems approach allows you to overcome barriers, abandon disjointed workflows and achieve standardization of insulin therapy across critical and non-critical care settings. It also addresses the important transitions between settings of care, including point of discharge. 

“Using the Glytec eGMS® platform translates to the difference between one order for insulin and 24 separate orders for insulin over the course of a six-day stay. Without eGMS®, clinicians have to manually perform all the dosing adjustments and manually enter all those orders. I can say with conviction, eGMS® not only delivers excellent clinical results, it is extremely efficient and time saving for clinicians.”


Jagdeesh Ullal, MD

Clinic Lead Inpatient and Subspecialty Diabetes, UPMC

Our evidence shows that best practice in subcutaneous insulin therapy improves patient safety, operational efficiency and cost of care.


1.67 days

reduction in average
length of stay1



first year savings (regional
medical center 610 beds)1

199.5 seconds

time saved per
prescriber per patient1


decrease in average
cost per case2

30 mins

time saved per
prescriber per shift1



increase in average
charge per case2



decrease in episodes
of severe hypoglycemia1



reduction in point of care
tests per patient3


Learn more about how to achieve full adoption of basal bolus.



  1. Safely Converting From Sliding Scale to Basal Bolus Insulin Across an Entire Medical Center via Implementation of the eGlycemic Management System. American Diabetes Association Scientific Sessions, June 2017.
  2. Data on file, unpublished.
  3. Implementation of the eGlycemic Management System: A Medical Center Case Study, International Hospital Diabetes Meeting, May 2017.